We Need Your help, NOW! Let’s secure 80MM new patients and create jobs for the profession.
If we don't make this change, other people who don't have your extensive training, will be treating your patients,
Watch this video to start!

State of the Profession Video link

Medicare Benefits
Click on Image to Enlarge

Old News, But a Reminder

WARNING LETTER from FDA to Hevert Pharmaceuticals LLC USAMARCS-CMS 594842 — JUNE 11, 2020
This letter is to advise you that the United States Food and Drug Administration (FDA) has reviewed your product labeling for your injectable products “Arnica,” “Calmvalera comp.,” “Gelsemium comp.,” “Hepar comp.,” and “Lymphaden comp.,” including your products’ labels and your website at, from which these products can be ordered. Based on our review, these injectable products are unapproved new drugs under section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355. Introducing or delivering these products for introduction into interstate commerce violates section 301 of the FD&C Act, 21 U.S.C. 331.

On  Nov 4, the CDC updated its

Clinical Practice Guidelines for Prescribing Opioids for Pain
It is notable that acupuncture is recommended over 40 times, more than any other therapy